Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence

Currently, limited data on targeted therapy and immunotherapy sequencing in patients with -mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-04, Vol.11 (8), p.2239
Main Authors: Rogala, Paweł, Czarnecka, Anna M, Cybulska-Stopa, Bożena, Ostaszewski, Krzysztof, Piejko, Karolina, Ziętek, Marcin, Dziura, Robert, Rutkowska, Ewa, Galus, Łukasz, Kempa-Kamińska, Natasza, Calik, Jacek, Sałek-Zań, Agata, Zemełka, Tomasz, Bal, Wiesław, Kamycka, Agnieszka, Świtaj, Tomasz, Kamińska-Winciorek, Grażyna, Suwiński, Rafał, Mackiewicz, Jacek, Rutkowski, Piotr
Format: Article
Language:English
Subjects:
Asymptomatic
Clinical medicine
Clinical trials
Data analysis
Immunotherapy
Medical prognosis
Melanoma
Metastasis
Mutation
Skin cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, limited data on targeted therapy and immunotherapy sequencing in patients with -mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics of patients who completed sequential treatment is needed. The primary objective of this study was to analyze the efficacy of BRAFi/MEKi activity as second-line therapy in patients with advanced melanoma. We also aimed to describe the clinical characteristics of patients with advanced melanoma who were treated sequentially with immunotherapy and targeted therapy. We enrolled 97 patients treated between 1st December 2015 and 31st December 2020 with first-line immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors; and for the second-line treatment with at least one cycle of BRAFi/MEKi therapy with follow-up through 31 January 2022. Median OS since first-line treatment initiation was 19.9 months and 12.8 months since initiation of BRAFi/MEKi treatment. All BRAFi/MRKi combinations were similarly effective. Median progression free survival (PFS) was 7.5 months since initiation of any BRAFi/MEKi treatment. BRAFi/MEKi therapy is effective in the second-line in advanced and metastatic melanoma patients. For the first time, the efficacy of all BRAFi/MEKi combinations as second-line therapy is shown.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11082239